Soleus Capital Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001802630

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q4 2024 · 81 positions · Total reported value $1.59B · Top-10 concentration 49.8% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 72.6% · 27 new · 36 cut · 27 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -6.9% · vs SPY -9.0% · Prev Value $2.90B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.4% · vs SPY -3.6% · Latest Value $2.81B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q4 2024 13F filing, Soleus Capital Management, L.P. disclosed 81 equity positions with a combined reported value of $1.59B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 49.8% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2024 were XBI ($270.18M), NVCR ($81.64M), TGTX ($80.71M). By sector, the heaviest allocations are Health Care 74.7%, Other 25.3%. Versus the prior quarter, allocation shifted toward Other (+3.7pp) and away from Health Care (-1.7pp), Industrials (-1.7pp).

Versus the prior quarter, Soleus Capital Management, L.P. opened 27 new positions, trimmed 36 and fully exited 27, a turnover rate of 72.6% of positions. The portfolio's overlap with the prior quarter was 51% of names.

The largest new positions opened in Q4 2024 were NVCR ($81.64M), BMRN ($65.82M), TEVA ($46.13M).

Of the 27 positions fully exited versus the prior quarter, the largest were SNY ($35.27M), IDYA ($33.24M), TXG ($21.47M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2024)

  • NVCR NOVOCURE LTD · $81.64M
  • BMRN BIOMARIN PHARMACEUTICAL INC · $65.82M
  • TEVA TEVA PHARMACEUTICAL INDS LTD · $46.13M
  • IART INTEGRA LIFESCIENCES HLDGS C · $28.94M
  • AZN ASTRAZENECA PLC · $26.80M
  • IKT INHIBIKASE THERAPEUTICS INC · $20.56M
  • ASND ASCENDIS PHARMA A/S · $19.82M
  • SEPN SEPTERNA INC · $15.47M

Fully Exited (vs previous quarter)

  • SNY SANOFI SA · prev qtr: $35.27M
  • IDYA IDEAYA BIOSCIENCES INC · prev qtr: $33.24M
  • TXG 10X GENOMICS INC · prev qtr: $21.47M
  • KROS KEROS THERAPEUTICS INC · prev qtr: $13.04M
  • BHC BAUSCH HEALTH COS INC · prev qtr: $11.62M
  • LBPH LONGBOARD PHARMACEUTICALS IN · prev qtr: $10.61M
  • ENTA ENANTA PHARMACEUTICALS INC · prev qtr: $8.14M
  • KIDS ORTHOPEDIATRICS CORP · prev qtr: $7.83M · history

Insider Transactions (Form 4)

Latest Soleus Capital Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-11 Conversion Parabilis Medicines, Inc. 527,070 $9.48 SEC filing
2026-06-11 Buy Parabilis Medicines, Inc. 125,000 $20.00 SEC filing
2026-06-11 Buy Parabilis Medicines, Inc. 375,000 $20.00 SEC filing

All insider transactions →

Fund Profile

Soleus Capital Management, L.P. is an SEC-registered 13F filer based in Greenwich, CT, United States. As of Q3 2026 it reported 97 US equity positions with a combined value of $2.81B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: GREENWICH, CT, United States
  • SEC registration: 801-118942 (status: Approved), registered 2020-06-25
  • Regulatory AUM (Form ADV): $3.66B as of 2026-04-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 12 private funds, of which 1 hedge funds

Portfolio Structure

  • 97 positions · $2.81B reported value (Q3 2026)
  • Top 10 holdings = 53.0% of reported value
  • Largest position: KRYS (KRYSTAL BIOTECH INC) at 13.5%
  • Average position size: $29.00M

Sector Tilt

  • Health Care 98.6%
  • Information Technology 0.0%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q3 2026: 27 new, 28 added, 36 reduced, 27 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 74.7%
Other 25.3%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 3.00M $270.18M 16.98%
16.98%
Add
2 2.74M $81.64M 5.13%
5.13%
New
3 2.68M $80.71M 5.07%
5.07%
Add
4 1.00M $65.82M 4.14%
4.14%
New
5 358.38K $56.14M 3.53%
3.53%
Add
6 6.61M $49.14M 3.09%
3.09%
Add
7 2.96M $48.71M 3.06%
3.06%
Reduce
8 6.56M $48.54M 3.05%
3.05%
Reduce
9 2.09M $46.13M 2.90%
2.90%
New
10 8.14M $45.11M 2.83%
2.83%
Add
11 12.48M $39.95M 2.51%
2.51%
Add
12 2.10M $39.62M 2.49%
2.49%
Add
13 109.39K $38.60M 2.43%
2.43%
Add
14 2.57M $33.58M 2.11%
2.11%
Add
15 2.49M $32.94M 2.07%
2.07%
Add
16 1.49M $31.95M 2.01%
2.01%
Add
17 1.28M $28.94M 1.82%
1.82%
New
18 2.43M $27.23M 1.71%
1.71%
Hold
19 409.00K $26.80M 1.68%
1.68%
New
20 6.98M $25.12M 1.58%
1.58%
Add
21 547.08K $24.37M 1.53%
1.53%
Reduce
22 320.27K $22.11M 1.39%
1.39%
Add
23 6.33M $20.56M 1.29%
1.29%
New
24 144.00K $19.82M 1.25%
1.25%
New
25 1.13M $19.02M 1.20%
1.20%
Add
26 243.54K $18.74M 1.18%
1.18%
Reduce
27 76.80K $18.07M 1.14%
1.14%
Add
28 2.98M $17.88M 1.12%
1.12%
Add
29 7.31M $16.15M 1.01%
1.01%
Hold
30 1.18M $15.62M 0.98%
0.98%
Add
31 814.65K $15.62M 0.98%
0.98%
Add
32 394.06K $15.60M 0.98%
0.98%
Reduce
33 675.41K $15.47M 0.97%
0.97%
New
34 312.32K $13.13M 0.82%
0.82%
Reduce
35 686.37K $11.98M 0.75%
0.75%
Add
36 205.29K $11.35M 0.71%
0.71%
Reduce
37 2.18M $11.29M 0.71%
0.71%
Reduce
38 275.00K $10.62M 0.67%
0.67%
New
39 801.00K $9.64M 0.61%
0.61%
New
40 328.58K $9.42M 0.59%
0.59%
Reduce
41 121.03K $9.28M 0.58%
0.58%
Add
42 11.66K $9.00M 0.57%
0.57%
Reduce
43 201.08K $8.80M 0.55%
0.55%
Reduce
44 4.80M $8.69M 0.55%
0.55%
Hold
45 104.36K $8.17M 0.51%
0.51%
Add
46 99.05K $8.11M 0.51%
0.51%
Add
47 697.16K $7.70M 0.48%
0.48%
Reduce
48 7.29M $7.29M 0.46%
0.46%
Hold
49 167.54K $7.24M 0.46%
0.46%
New
50 252.92K $6.74M 0.42%
0.42%
Reduce

FAQ

What did Soleus Capital Management, L.P. buy in 2024-Q4?

In its 2024-Q4 13F filing, Soleus Capital Management, L.P. reported 81 equity positions worth $1.59B in aggregate; its largest disclosed positions were XBI ($270.18M), NVCR ($81.64M), TGTX ($80.71M).

How large is Soleus Capital Management, L.P.'s portfolio?

Soleus Capital Management, L.P. reported $1.59B of long equity holdings across 81 positions as of 2024-Q4. Top-10 holdings account for 49.8% of reported value.

What is Soleus Capital Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/soleus-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →